Brought to you by 
Sanofi pays €400mm up front for rights to Hanmi's Quantum Project in diabetes; deal amended
25 Sep 2017
Executive Summary
Sanofi licensed exclusive global rights to three of Hanmi Pharmaceutical Co. Ltd. diabetes candidates which together make up the company's Quantum Project.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sanofi pays €400mm up front for rights to Hanmi's Quantum Project in diabetes; deal amended
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice